Introduction
An earlier paper in this series showed why systematic reviews are more reliable than other forms of review, such as the narrative commentary [1] . This paper takes this further by examining why systematic reviews which use individual patient data (IPD) are regarded as more reliable than other forms of systematic review [2] . It illustrates how the IPD approach can help achieve the ultimate aim of any systematic review of randomised controlled trials: the inclusion of all randomised patients in all relevant trials, analysed in accordance with the treatment allocated at randomisation. This paper highlights why IPD reviews might be particularly useful in cancer. It does not argue that all systematic reviews need to be done in this way. The most appropriate way in which to conduct any systematic review depends very much on the health care question being addressed by that review. IPD reviews have a number of benefits over other forms of systematic review and these are discussed in this paper, along with some possible disadvantages. In addition, some of the relatively little empirical research comparing IPD reviews with those based solely on published results is outlined. This research has shown that IPD reviews can produce importantly different results, generally finding lower estimates of treatment effect and less statistically significant results (Table 1) . This paper contains a new comparison which shows that the reverse can also happen: the IPD review provides a larger, more significant estimate of treatment effect than would have been found with a review based solely on published data.
What are individual patient data reviews?
In any systematic review the first, and perhaps most important, step is to identify all relevant trials. If appropriate, the results of these trials are then combined in a meta-analysis. In an IPD review, the separate trial results to be used in the meta-analysis come from a central analysis of the raw data from each trial. In order to do this, a limited amount of information on each patient entered into each identified trial must be collected centrally, usually by a small secretariat. Any apparent inconsistencies or problems are discussed and, hopefully, resolved by communication with the responsible trialists. The finalised data for each trial are then analysed separately to obtain summary statistics, which are combined to give an overall estimate of the effect of treatment. In this way, patients in one trial are compared directly only with other patients in the same trial.
The use of IPD in a systematic review shares benefits, resulting from direct contact between reviewers and Table 1 . Some previous comparisons of IPD reviews with reviews using published data alone.
1. The effect on mortality of single non-platinum drugs versus platinumbased combination chemotherapy for ovarian cancer [3] . Published data review: eight trials, 788 patients, 0.71 (0.52-0.96); 2p = 0.027. IPD review: 11 trials, 1329 patients, 0.93 (0.83-1.05); 2p = 0.30. Main reasons for the reduced estimate in the IPD review:
-publication bias has been minimised; -inappropriate exclusion of patients from the published data; -improved follow-up in the IPD review; -method of analysis.
2. The effect on mortality of thoracic radiotherapy versus control for small-cell lung cancer [4] . Published data review: 11 trials, 1911 patients, 0.65 (0.53-0.83); 2p < 0.001. IPD review: 13 trials, 2103 patients, 0.83 (0.76-0.92); 2p < 0.001. Main reasons for the reduced estimate in the IPD review:
-improved follow-up in the IPD review; -method of analysis.
3. The effect on live births of paternal white blood cell immunization versus control for recurrent miscarriage [5] . -publication bias has been minimised; -inclusion of additional patients from the published trials. Possible additional benefits of involving the relevant trialists in the conduct of the review: -better identification of trials; -more balanced interpretation of the results of the review; -wider endorsement; -increased possibilities for dissemination of the results of the review; -better clarification of the implications for future research; -possibilities for collaboration in future research.
Possible additional benefits of using individual patient data:
-analyze by time to event; -increase statistical power; -more flexible analysis of patient subgroups; -more flexible analysis of outcomes; -might be easier for trialists to supply individual patient data than to prepare tables; -easier for trialists to supply small amounts of additional or new data; -data can be checked and corrected.
Possible disadvantages of ipd reviews:
-make take longer and cost more; -reviewers need wider range of skills; -inability to include IPD from all relevant trials.
trialists, with reviews that use updated aggregate data provided by the trialists. In addition it provides a number of additional benefits that cannot otherwise be achieved readily but it also has some possible disadvantages. Several of these features are shown in Table 2 and a selection are discussed here.
Inclusion of unpublished trials
The need to try to include all, or nearly all, of the relevant trials in a systematic review has been discussed earlier in this series [1] . This is probably the most important aspect of any systematic review since it will increase the amount of data available for analyses and it will reduce the possibility that the trials included in the review represent a biased set of trials, where this bias is related to the results of the trials ('publication bias'). Typically, this means that trials with positive results are more likely to be published than those with null or negative results [6] . To minimise this, the trial finding process for any systematic review needs to involve more than a simple search for published papers in electronic sources such as the Cochrane Controlled Trials Register [7] or MEDLINE. A range of other sources of information should be used and an important advantage of actively involving the trialists in a systematic review is that they can help with this. The trialists may know of trials that are unknown to the reviewers, perhaps those that they themselves have conducted or ones with which they are familiar through knowledge of work by colleagues. The trialists might also help by doing their own searches for trials: through discussions with colleagues, electronic searches of relevant databases or hand-searching of the published literature. This might be of particular benefit where English is not the main language of publication for some of these trials.
Improved follow-up
Death is often the most important outcome in trials of treatments for cancer. If the disease has a very poor prognosis, follow-up of a few years might be sufficient to obtain a reliable estimate of the relative efficacy of the treatments under investigation since most patients will not survive beyond this time. However, in other cancers, such as resectable breast cancer, a majority of patients will survive several years and it could be decades before a reliable estimate of the mortality effects of various treatments can be made. This might not be possible with published data, since these are 'frozen-in-time' by the publication process. This can be overcome if the trialist has maintained the data in their trial and if the updated results can be obtained for the review. Beyond this, if a set of individual patient records can be collected from the trialist, it may be possible for the organisers of the review to track the history of patients long after the original trial organisation has stopped doing so [8] . The reviewers should also endeavour to ensure that their results do not become 'frozen-in-time'. Many IPD reviews are conducted on a cyclical basis with data collection, analyses and dissemination taking place every few years. The establishment of the Cochrane Collaboration provides a means by which a wider range of reviews can be periodically updated [9] . Such updating not only allows increased follow-up to be used for the trials already included but also allows the reviewer to add in the results of additional trials.
Time-to-event analyses
A major benefit of collecting IPD follows on from this, since IPD will allow analyses not just of whether an outcome has happened but also when it happened. Where the outcome of interest is death, the issue of whether one treatment leads to a prolongation of survival can be investigated. This would not be possible if data for a fixed point in time were collected and if it was to be attempted from aggregate data this would need to be collected for a series of points in time. IPD also means that the sequence of events (for example different types of relapse at different times) can also be analysed properly, and differences in follow-up between the treatment groups can be identified more readily.
Intention-to-treat analyses
All randomised patients should be included in the analysis in accordance with the treatment allocated at randomisation (an 'intention-to-treat' analysis). In this way, the policy of using one treatment will be appropriately compared to the policy of using another [10] . Unfortunately, many randomised trials do not follow this principle when publishing their results and patients are excluded for a variety of reasons. Sometimes these reasons will seem unconnected to the assigned treatment, for example when the delayed result of a pre-randomisation diagnostic test reveals that the patient was ineligible for the study. More seriously, they can be treatment related if, for example, the patient was unable to tolerate the allocated treatment or they failed to follow the treatment schedule for some other reason. If data are collected from trialists they can be explicitly asked to supply this on the basis of the allocated treatment so that an intention-to-treat analysis can be performed. If IPD are collected then this can often be checked to identify whether any imbalances in the data indicate that there may have been some post-randomisation exclusions.
Subgroup analyses
Subgroup analyses can often lead to misleading conclusions in small trials or reviews [11] . If large-scale randomised evidence is available, these can be used, with appropriate caution, to assess whether the differences between treatments are greater for particular groups of patients and, perhaps, to generate hypotheses for testing in future trials. If subgroup analyses are to be done, they should be as complete as possible and involve commonly defined subgroups and outcomes across all the trials. This will rarely be possible with published data alone. Even if every relevant trial had been published, the details published on various subgroups might be both incomplete and biased. Although trialists could be asked to fill in a table containing aggregate data on different types of patient and of outcome, this might prove difficult. Each trialist would need to adopt the centrally determined definitions for particular subgroups and outcomes. In addition, if the outcome data had also to be supplied for different lengths of follow-up, the necessary tables could become extremely complex. Thus, the collection of IPD is likely to prove simpler for many trialists. It also allows the secretariat to prepare the necessary files for analysis and to apply consistent definitions across the included trials.
Rare events
As already noted, the collection of long-term follow up for the reviewed trials may allow a more reliable investigation of the effects of treatment on overall mortality.
This might be especially important for the investigation of serious long-term side effects, such as second cancers. The collection of IPD is particularly helpful in this and may be the best way for some long-term effects to be assessed. By periodically collecting updated data on each patient, the amount of follow-up can be continually extended. If the endpoint of interest is a particular cause of death this can sometimes be achieved through the use of national mortality records (either by the trialists or the reviewer) [8] . Similarly, cancer registries, where these exist, might be used to help collect data on the diagnosis of second cancers. If a central database has already been prepared which contains the necessary baseline data for each patient, it is relatively easy to add any new followup information that becomes available.
What if IPD are not available?
One possible disadvantage of attempting to do an IPD review is that it may not always be possible to collect IPD from all relevant trials. Some trialists may be unwilling or unable to provide data on individual patients but might be willing to supply updated aggregate data. Others might not wish to collaborate in the project and will therefore not supply any material. It might prove impossible to locate the trialists responsible for some of the identified trials. The approach taken for the review will depend on how much IPD it has been possible to collect from the other relevant trials. If the number of trials for which IPD are not available is so small that the proportion of missing data is too small to affect the results of the review in any important way, it is probably not worth trying to include results from these trials. It might be preferable to wait and to continue trying to obtain the IPD so that it can be used in a future review. If, however, the proportion of non-IPD material could importantly influence the conclusions of the review then it might be necessary to try to include some data from these trials and the benefits of the IPD approach may be diminished.
Examples
To illustrate the issues that have been discussed above with practical examples, two reviews have been chosen from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) overview of treatments for breast cancer. This project currently involves the central collection of data on more than 130,000 randomised women and the collaboration of more than 200 trial organisations from around the world to allow IPD reviews of a range of treatments for early (ie apparently resectable) breast cancer. The EBCTCG was formed in 1983 when a limited amount of aggregate data was sought from identified trials which had compared tamoxifen versus control, or conventional chemotherapy versus control. It became apparent that this was insufficient and it was agreed that a limited amount of data should be collected on each and every woman randomised into these trials so that more detailed analyses could be performed [12] . This was done and the results were reported in brief in 1988 [13] and in more detail in 1990 [14] . At the same time, it was decided to expand the EBCTCG overview to encompass all randomised trials of any aspect of the treatment of early breast cancer. The eligibility criteria were simply that the trial began before 1985, the method of treatment allocation should prevent foreknowledge of the next treatment to be assigned, and that survival was one of the primary endpoints. Trials which investigated treatments such as ovarian ablation, radiotherapy and surgery were brought fully into the process. This means that the EBCTCG overview needs to employ a wide range of strategies to identify relevant trials. In addition to the searching of bibliographic databases, other sources of information used include the proceedings of relevant meetings; registers or databases of trials; and contact with individuals, pharmaceutical companies and trial groups who may know of relevant studies. The IPD reviews for systemic or adjuvant therapies were published at the beginning of 1992 [15] and, for trials of different forms of local therapy (ie surgery and radiotherapy), three years later [16] . The third cycle of the overview began in 1994. The eligibility date was moved so that trials beginning during 1985-1989 became eligible. Data were sought from these trials, along with further follow-up information for the women on whom data had already been collected. To date, the IPD reviews for ovarian ablation [17, 18] , and for tamoxifen [19] have been published. These reviews provide the illustrative examples for this paper.
Ovarian ablation
In the EBCTCG overview of ovarian ablation versus control, a combination of more complete trial identification and inclusion, improved follow-up and the ability to do time-to-event analyses meant that the 1992 finding of a substantial 15-year survival benefit among women under 50 years of age was generally unexpected [20] . The reasons for this can be investigated by comparing the results of the IPD review with what might have been found by a review relying on published data alone if one had been done at the same time. Published results were extracted from all relevant publications (including full papers or abstracts) which had been published before September 1990 (when the overview results were first presented to the EBCTCG) so that the publication status of each trial could not have been influenced by knowledge of the results of the overview. The second source of data are the results of intention-to-treat analyses of the IPD supplied for use in the overview. Again, to avoid the possibility of bias, data supplied prior to the 1990 EBCTCG meeting have been used.
The data extracted from each publication were chosen so as to be as similar as possible to those which were analysed in the overview. The ideal was to extract the number of women under 50 years of age who were randomised and the number who had died in each treatment group. Where this was not possible, the published values closest to this were used. In most cases these had to be restricted to women who were pre-or perimenopausal at randomisation, and who were classified as eligible or evaluable for the published analyses. If a trial had been published more than once, the data which provided the maximum amount of randomised evidence were used. Typically, the results were taken from the publication with longest follow-up. The data extracted from the published reports were analysed using the assumption-free (or 'fixed effects') model. The IPD were analysed using log-rank methods. The following analyses generally report the results as odds ratios (OR), along with their 95% confidence interval (CI). If the confidence interval overlaps 1.00, the result is not statistically significant as it is consistent, at this level of probability, with no difference between ovarian ablation and control.
In 1990, twelve trials were deemed relevant for inclusion in the EBCTCG overview (Table 3) . IPD were available for ten of these, five of which had published details of the number of women randomised to each arm along with some mortality information. Two of the unpublished trials (Ontario and Caen) were studies for post-menopausal women and consequently contribute little data (nine and one women respectively under 50 years at randomisation) to these analyses. The number of women and deaths in each arm could be extracted from the publications of the two trials for which IPD were not available.
The meta-analysis of published data from seven trials (a total of 417 deaths in 1644 women) shows no significant difference (OR: 0.86; 95% CI: 0.68-1.07). Given that such an analysis might have been expected to overestimate the true effect of ovarian ablation because of the issues noted in Table 1 (such as publication bias and the possible selective exclusion of randomised patients) it might have been concluded that ovarian ablation would not be shown to have much, if any, survival advantage when subjected to an IPD review. In fact, in 1992, the IPD review for 10 trials (720 deaths in 1746 women) actually found that the published data metaanalysis would have been an under-estimate. This review showed a 24% SD 7 reduction in the annual odds of death in favour of ovarian ablation, equivalent to an OR of 0.76 (95% CI: 0.65-0.88; 2p = 0.0004) [12] . Time-toevent analyses are also possible with IPD and a survival curve was produced which revealed that there was no significant difference in survival for women in the two treatment groups for the first few years after randomisation but that an increasing benefit became apparent with more follow-up. The absolute survival advantage for women allocated to ovarian ablation was highly significant by 15 years: 10.2% SD 2.7 (log-rank 2p = 0.0004) [15] . The larger effect in the IPD review stems primarily from the positive impact of using additional follow-up and time-to-event analyses. This more than compensates for the negative impacts of removing publication bias and standardising the analyses across all the trials.
To investigate this further, IPD analysis of the five published trials which supplied this gives an OR of 0.72 (0.61-0.86) which is highly significantly in favour of ovarian ablation. In contrast, the published data for these five trials yields a smaller estimate for the effect of ovarian ablation which, again, is not significant (OR: 0.81; 0.63-1.03). However, if the IPD analysis is restricted to the number of deaths by three years (which was the usual period of follow-up in the published reports) the result also shows a smaller and non-significant benefit (0.85; 0.63-1.14) than that found using the maximum possible follow-up.
There are too few trials in this review to investigate reliably whether it contains evidence for a results-related publication bias, primarily because there is relatively little data in the unpublished trials. Analysis of the IPD for the 1145 women (584 deaths) in the five trials that had been published by 1990 gives an OR of 0.72 (0.61-0.86) compared to an OR of 0.93 (0.65-1.31) for the 601 women (136 deaths) in the five unpublished studies.
These findings are based on the results of the second cycle of the EBCTCG overview and because this project is conducted every five years, the results of the third cycle which began in 1995 are now available. This updating process, meant that further follow-up could be included for most of the ten trials included in the 1990 overview and that two additional trials could be added [17, 18] . One of these, NSABP B-03 [21] , was a trial for which data were not available in 1990 but became available over the ensuing years.
The particular benefits of using IPD for the ovarian ablation review were, therefore,
-the results of unpublished trials could be included; -improved follow-up information could be used for each trial; -time-to-event analyses could be performed.
Tamoxifen
In the EBCTCG overview, data are collected for each individual woman which includes her age, menopausal status, nodal status, hormone receptor measurements and allocated treatment when randomised. Information which is as up-to-date as possible is also collected on the dates of randomisation, second primary cancer, first recurrence, first distant recurrence, and of most recent follow-up or death. If a woman died without a recorded recurrence, details of her cause of death are sought. All of this information contributed to the recent publication of the IPD review of adjuvant tamoxifen versus control, which included 37,000 women in 55 separate randomised trials [19] .
The review showed that some of the assumptions on which much current practice is based are not supported by the evidence [28] . The analyses revealed that, for every twelve women with hormone-sensitive disease who were treated with five years of tamoxifen, two fewer would have relapsed within the first ten years and one fewer would have died. This was found for women who were above or below 50 years of age, in women who were node negative or node positive, and whether or not adjuvant chemotherapy was also used. If these issues were to be investigated with aggregate data rather than IPD, each trialist would need to supply tables divided by at least two age groups, at least two nodal status categories and at least two hormone receptor measurement values. Each table would need to cover at least two outcomes and, in order to investigate changes over different periods of follow-up, be completed for at least two timepoints. If possible interactions between any two categories were to be investigated, even more tables would be needed. In contrast, the collection of IPD allowed all these factors to be analysed and these analyses could be performed in the same way in each trial.
The tamoxifen review was also able to address reliably the issue of the serious side effects of this drug. This was possible through the collection of data on causespecific mortality and on the incidence of second cancers, and because so many patients are included: 37,000 randomised women in total. The review showed that, in terms of adverse, serious side effects, there was an increase in the incidence of endometrial cancer and in deaths from this among women in the tamoxifen group. However, this was more than out-weighed by the beneficial, serious side effect: tamoxifen reduces the incidence of contralateral breast cancer. The review also showed that, apart from breast cancer and endometrial cancer, there was no statistically significant increase or decrease in the incidence of any other cancer or any other major cause of death in women allocated adjuvant tamoxifen. Overall, among every 1000 women with breast cancer, about five years of adjuvant tamoxifen reduced the number of deaths due to breast cancer by about 80 and increased deaths from other causes by just three during the first ten years after diagnosis [19] .
The particular benefits of using IPD for the tamoxifen review were, therefore, -the ability to ensure that subgroup analyses could be performed consistently across all the trials; -the ability to investigate outcomes which are rare.
Discussion
Systematic reviews of randomised trials are increasingly important as means of assessing the relative benefits of different forms of treatment, not least because of the work of the Cochrane Collaboration in establishing a process for the conduct of such reviews throughout health care. IPD reviews in cancer are also becoming more common [29] . This paper describes some of the benefits if reviews use IPD and illustrates these with examples from the EBCTCG overview of treatments for breast cancer. It is, therefore, primarily concerned with the output from a long-standing, major collaborative project, and, as such, the findings cannot necessarily be extrapolated to other areas of cancer or health care more generally. There can be no guarantee that the use of IPD led to results that are materially different from those that would have been obtained if the trialists had been asked to supply updated, aggregate data instead, since the latter option was not taken.
Any attempt to make such a comparison using material from the EBCTCG overview would be confounded by several factors. For example, influences such as the ongoing, worldwide collaborative nature of the overview; the ability to identify and rectify problems that might be seen in the IPD but missed if aggregate data were supplied; and the perception of reliability given to the overview process by those consulting its results would all need to be considered if a thorough and reliable investigation of the two techniques for systematic review -updated IPD or updated aggregate data -was to be undertaken. Likewise, it is difficult to make a judgement about the relative value of different forms of systematic review on the basis of the time and resources needed for an IPD review in comparison to those needed for other types of systematic review. Even if the results of a review conducted in two different ways were identical, and one was quicker and cheaper than the other, one would need to place a value on the reliability of the two approaches before deciding which was the 'better'. This paper shows that an IPD review can produce very important results that might not have been obtainable in any other way. Without the ability to analyse data on each of the women who took part in these randomised trials and to update this with follow-up information collected after the results of some of the trials had been published, the important findings discussed above would not have come to light.
